CAN SDAI REMISSION BE PREDICTED IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS TREATED WITH ANTI-TNF AGENTS?
Romanian Journal of Rheumatology · 2015
DOI: 10.37897/rjr.2015.2.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Romanian Journal of Rheumatology, 2015. Verfasst von Cristina Pomirleanu und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Objective
To identify predictors for Simplified Disease Activity Index (SDAI) remission in established rheumatoid arthritis (RA) and to develop a predictive score for remission.
Methods
Prospective 12-month observational study in ninety active RA receiving their first TNF-α inhibitor. Standard assessments consisted of disease activity scores (DAS28-ESR, SDAI) and immune parameters (total rheumatoid factor, RF; IGA-RF; anti-cyclic citrullinated peptide antibodies, ACPA). The primary outcome measure was SDAI remission (≤ 3.3) at 12 months. Univariate and multivariate logistic regression models were used to estimate association between baseline variables and SDAI remission.
Results
39.7% RA achieved remission, while 56.8% low disease activity. Significant association between SDAI remission and RA-onset before 50 (p = 0.000), history
Zitieren
APA
Pomirleanu, C., Jitaru, A., Maxim, R., Belibou, C., & Ancuta, C. (2015). CAN SDAI REMISSION BE PREDICTED IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS TREATED WITH ANTI-TNF AGENTS?. Romanian Journal of Rheumatology. https://doi.org/10.37897/rjr.2015.2.4
Vancouver
Pomirleanu C, Jitaru A, Maxim R, Belibou C, Ancuta C. CAN SDAI REMISSION BE PREDICTED IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS TREATED WITH ANTI-TNF AGENTS?. Romanian Journal of Rheumatology. 2015. doi:10.37897/rjr.2015.2.4
BibTeX
@article{Pomirleanu2015,
author = {Pomirleanu, Cristina and Jitaru, Alexandra and Maxim, Raluca and Belibou, Codruta and Ancuta, Codrina},
title = {CAN SDAI REMISSION BE PREDICTED IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS TREATED WITH ANTI-TNF AGENTS?},
journal = {Romanian Journal of Rheumatology},
year = {2015},
doi = {10.37897/rjr.2015.2.4}
}
EUVIMED